Cardiac Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Cardiac Biomarkers Market is segmented by Type (Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, and Others), Application, Location of Testing and Geography

Cardiac Biomarkers Market Snapshot

Cardiac Biomarkers Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >8.5 %
Cardiac Biomarkers Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Biomarkers enable the timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. According to WHO, around 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Myocardial infarction is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. A timely diagnosis of heart conditions allows clinicians to analyze the risk of their patients and prescribe relevant treatment. The increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements is expected to drive the market in the forecast period.

Scope of the Report

As per the scope of the report, Biomarkers have an essential role in the diagnosis, management, risk stratification, and clinical decision-making in the patients suffering from disease. Cardiac biomarkers are measurable and quantifiable biological parameters, which are detected in the blood and serve as indices for physiological and pathological assessment.

By Type
Creatine Kinase
Ischemia Modified Albumin
By Application
Congestive Heart Failure
Acute Coronary Syndrome
Myocardial Infarction
By Location Of Testing
Point of Care Testing
Laboratory Testing
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Myocardial Infarction Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Others. The key factor contributing to the growth of the segment is the rising number of cardiovascular disorders. According to the American College of Cardiology, approximately every 40 seconds, an American will have a myocardial infarction. The average age of first myocardial infarction is 65.6 years old for men and 72.0 years old for women. Many companies are focusing on developing breakthrough products for the treatment of cardiovascular disease. Hence, with the rising government initiatives and wide applications of biomarkers in cardiac diagnostics, the market is expected to grow over the forecast period.

Cardiac Biomarkers Market Key Trends

North America Dominates the Cardiac Biomarkers Market

The cardiac biomarkers market holds the largest share in North America region. According to the American Heart Association around 2,300 Americans die of cardiovascular disease each day. The cardiac markers help in monitoring the prognosis of certain condition with greater accuracy and providing the most effective treatment to the patients Hence, with the rising concerns regarding cardiovascular disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Cardiac Biomarkers Market Growth by Region

Competitive Landscape

The global players in the cardiac biomarkers market are - Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Randox Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Cardiovascular Diseases

      2. 4.2.2 Technological Advancements in the Cardiac Biomarkers

      3. 4.2.3 Growing Funding From Public and Private Organizations for R&D

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Framework

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Creatine Kinase

      2. 5.1.2 Troponins

      3. 5.1.3 Myoglobin

      4. 5.1.4 Ischemia Modified Albumin

      5. 5.1.5 Others

    2. 5.2 By Application

      1. 5.2.1 Congestive Heart Failure

      2. 5.2.2 Acute Coronary Syndrome

      3. 5.2.3 Myocardial Infarction

      4. 5.2.4 Atherosclerosis

      5. 5.2.5 Others

    3. 5.3 By Location Of Testing

      1. 5.3.1 Point of Care Testing

      2. 5.3.2 Laboratory Testing

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 BioMerieux

      4. 6.1.4 Bio-Rad Laboratories, Inc.

      5. 6.1.5 Danaher Corporation

      6. 6.1.6 F. Hoffmann-La Roche AG

      7. 6.1.7 Randox Laboratories

      8. 6.1.8 Siemens Healthineers

      9. 6.1.9 Thermo Fisher Scientific

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cardiac Biomarkers Market market is studied from 2018 - 2026.

The Cardiac Biomarkers Market is growing at a CAGR of >8.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Abbott Laboratories, Becton, Dickinson and Company, BioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation are the major companies operating in Cardiac Biomarkers Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!